# ERNA — Ernexa Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ERNA  
**Sources:** 18  
**Published:** 2026-10-26  
**Canonical:** https://app.k3vl4r.com/research/deep-research-erna-ernexa-therapeutics-inc-catalysts-narrative-risks-9363

---

## Ernexa Therapeutics Inc. (NASDAQ: ERNA) — Research Snapshot (as of 2026-10-26)

**Company / asset profile.** Ernexa Therapeutics is a Cambridge, Massachusetts-based, preclinical-stage biotech developing allogeneic, "off-the-shelf" cell therapies built on an induced pluripotent stem cell (iPSC)-to-induced mesenchymal stem cell (iMSC) platform, using patented mRNA cell engineering technology [[15]](https://stockanalysis.com/stocks/erna/), [[18]](https://investor.ernexatx.com/). The company was formerly known as Eterna Therapeutics [[15]](https://stockanalysis.com/stocks/erna/). Its lead oncology program, ERNA-101, is an IL-7/IL-15 (fusokine)-secreting iMSC engineered for ovarian cancer [[2]](https://finance.yahoo.com/healthcare/articles/ernexa-therapeutics-erna-101-selected-125500278.html), [[15]](https://stockanalysis.com/stocks/erna/). ERNA-201 is an anti-inflammatory (IL-10) secreting iMSC program for rheumatoid arthritis/inflammatory disease [[15]](https://stockanalysis.com/stocks/erna/).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-erna-ernexa-therapeutics-inc-catalysts-narrative-risks-9363 (free to sign up)._